Recruiting
Early Phase 1

Ivabradine

Sponsor:

University of British Columbia

Code:

NCT07717710

Conditions

Healthy Adult

Eligibility Criteria

Sex: All

Age: 19 - 70+

Healthy Volunteers: Accepted

Interventions

Ivabradine (single oral dose)

Study Details

Brief summary:

During exercise, working muscles require more oxygen. The heart meets this demand in two ways: by beating faster (heart rate) and by pumping more blood with each beat (stroke volume). Heart rate increases steadily with exercise intensity until exhaustion, but the amount of blood pumped with each beat tends to plateau at moderate intensities. Why the amount of blood pumped with each beat becomes limited before heart rate, however, is not well understood.

Studying these mechanisms is difficult because most drugs that lower heart rate also affect how strongly the heart pumps, making it hard to separate the two effects. One medication that can help with this is ivabradine, which is used to treat people with heart disease who have high resting heart rates. It slows the heart rate without changing how strongly the heart pumps.

This study will investigate whether ivabradine lowers heart rate during exercise in healthy younger and older adults, and whether a higher dose lowers heart rate more. The results will help us better understand how heart rate influences the heart's ability to supply oxygen to the body during exercise, and what limits the ability to exercise as people age.

Participants will:

  • Attend three visits at SportsCardiologyBC in Vancouver
  • Complete a cycling exercise test at each visit to measure heart rate and how hard they can exercise
  • Take ivabradine (a heart-rate-lowering medication) before the exercise test at Visits 2 and 3 (a lower dose at Visit 2 and a higher dose at Visit 3)
  • Be monitored for side effects including slow heart rate, visual symptoms, and headache.

Conditions

Healthy Adult

Study ID

NCT07717710

Start date

Oct 1, 2026

Status verified date

Jul, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 19 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Healthy males and females aged 19-39 years, and 60-79 years
  • Engaging in regular aerobic exercise (e.g., running, cycling, swimming, hiking, field, ice, or racquet sports) at least once per week

Exclusion Criteria:

  • History of any cardiovascular condition, including hypertension
  • Use of any chronic medication
  • History of any respiratory condition, including asthma
  • Smoking, including cannabis or vaping in the past year
  • History of diabetes mellitus, cancer, hepatic, renal or any other chronic illness
  • Seated blood pressure ≥130/90 or <100/60 mmHg
  • Body mass index <20 or >32 kg/m2
  • Non-sinus rhythm or abnormalities on 12-lead electrocardiogram (ECG)
  • Pregnant, breastfeeding, or women of childbearing potential not using appropriate contraception
  • Current or recent (past year) participation in >150 minutes per week of moderate-vigorous intensity exercise (to avoid endurance training-related bradycardia)
  • Any condition that prevents vigorous exercise from being performed safely
  • Seated resting heart rate <60 beats per minute
  • Prolonged QT interval (e.g., long QT syndrome)
  • Sick sinus syndrome, sino-atrial block or third-degree atrio-ventricular block
  • Use of strong cytochrome P450 (CYP3A4) inhibitors (e.g., nirmatrelvir and ritonavir, ketoconazole), which can increase ivabradine levels in the blood to potentially unsafe levels
  • Use of verapamil or diltiazem, which are moderate CYP3A4 inhibitors and also lower heart rate, posing a risk of excessive bradycardia when combined with ivabradine
  • Lactose intolerance, as ivabradine contains lactose
  • Known allergy/hypersensitivity to ivabradine or to any ingredient in the formulation or component of the container

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Ivabradine

All participants receive two single oral doses of ivabradine in a fixed sequence across separate experimental visits.

Interventions

Ivabradine (single oral dose)

A single oral dose of ivabradine is administered at each experimental visit, in a fixed order: 7.5 mg at Visit 2 (one 7.5 mg tablet), and 12.5 mg at Visit 3 (one 7.5 mg + one 5 mg tablet).

Ivabradine is a selective hyperpolarization-activated cyclic nucleotide-gated transmembrane (HCN4) channel inhibitor that reduces heart rate without affecting myocardial contractility.

Primary outcome measure

  • Heart rate, peak [ Time Frame: Within 30 minutes of exercise onset ]

Central Contacts and Locations

Central contacts

Stephen P Wright, PhD

604-806-9292stephen.wright@ubc.ca

Nathaniel Moulson, MD, MPH

604-822-9494nathaniel.moulson2@vch.ca

Locations

SportsCardiologyBC, UBC Hospital

Recruiting

Vancouver, British Columbia, Canada, V6T 2B5

Contacts

Stephen P Wright, PhD

604-806-9292stephen.wright@ubc.ca

More Information

Sponsor

University of British Columbia

Last update posted

Oct 9, 2026

Last verified

Jul, 2026

Keywords

  • Heart rate regulation
  • Stroke volume
  • Cardiac output
  • Exercise
  • Exercise capacity

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-10. This information was provided to ClinicalTrials.gov by University of British Columbia on 2026-10-09. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.